Zoetis
ZTS
$72.66
-5.97%
Zoetis Inc. is the world's largest animal health company, developing and manufacturing vaccines, anti-infectives, parasiticides, diagnostics, and other health products for livestock and companion animals. The company holds a dominant market share in the veterinary pharmaceutical industry, with a diversified portfolio spanning production animals (cattle, swine, poultry) and companion animals (dogs, cats, horses), and was spun off from Pfizer in 2013. Currently, the stock is under intense scrutiny as it faces a sharp decline in share price—down over 47% in the past year—amid concerns about slowing growth in key segments, competitive pressures, and a challenging macroeconomic environment. Analysts are questioning the company's pathway to growth, while management's guidance and recent earnings have provided mixed signals, keeping the investment community divided on the stock's future prospects.…
ZTS
Zoetis
$72.66
Related headlines
Investment Opinion: Should I buy ZTS Today?
Based on the analysis, I rate Zoetis as a Hold. The company is a high-quality business with a dominant market position, strong margins, and a reasonable forward valuation, but the current growth deceleration and negative price momentum warrant caution. The analyst consensus is a Buy with an average target of $110.81, implying 43.4% upside, but the wide target range and recent downgrades suggest significant uncertainty.
Sign up to view all
ZTS 12-Month Price Forecast
The AI assessment is neutral, reflecting the conflicting signals. On one hand, the forward valuation is attractive, and the company has a dominant market position with strong margins. On the other hand, the growth deceleration is real, and the stock is in a clear downtrend. The key factor to watch is whether revenue growth can re-accelerate, which would validate the forward PE and drive the stock higher. If growth continues to stagnate, the stock could fall further. The stance would upgrade to bullish if revenue growth exceeds 5% and the stock breaks above $85, or downgrade to bearish if revenue growth turns negative or the stock breaks below $71.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Zoetis's 12-month outlook, with a consensus price target around $104.19 and implied upside of +43.4% versus the current price.
Average Target
$104.19
0 analysts
Implied Upside
+43.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $160
Analyst target range
The target price range spans from $80.00 to $160.00, with a wide spread of $80.00, indicating high uncertainty about the stock's future. The high target assumes a full recovery to previous highs, likely driven by a rebound in companion animal growth and successful new product launches. The low target implies that the stock could remain near current levels if growth continues to stagnate and competitive pressures persist. Recent institutional ratings show a mix of actions, with HSBC and TD Cowen maintaining Buy ratings, while Argus Research downgraded from Buy to Hold in May 2026, reflecting growing caution. The wide target spread and mixed ratings suggest that the market is deeply divided on Zoetis's ability to regain its growth momentum.
Drowning in data?
Find the real signal!
Bulls vs Bears: ZTS Investment Factors
Zoetis presents a classic value trap scenario: a dominant company with strong profitability but facing a significant growth slowdown. The bull case rests on the company's market leadership, high margins, and attractive forward valuation, while the bear case highlights the sharp deceleration in revenue, massive stock decline, and high leverage. Currently, the bearish evidence is stronger, as the growth deceleration is real and the stock is in a clear downtrend. The most important tension is whether the company can reignite growth in its companion animal segment, which would validate the forward PE and analyst targets. If growth resumes, the stock could recover significantly; if not, the stock may continue to drift lower.
Bullish
- Dominant market position in animal health: Zoetis is the world's largest animal health company with the largest market share in the industry, benefiting from a diversified portfolio across companion and production animals. This scale provides pricing power and resilience, as evidenced by a gross margin of 70.5% and an operating margin of 38.0% in the latest quarter.
- Strong profitability and cash generation: The company maintains high profitability with a net margin of 28.2% and generates substantial free cash flow of $2.136 billion TTM. This financial strength supports continued investment in R&D and shareholder returns, including a dividend yield of 1.59%.
- Attractive forward valuation: The forward PE of 10.46x is significantly lower than the trailing PE of 20.87x, implying the market expects a sharp earnings recovery. If EPS reaches the analyst consensus of $9.34, the stock would trade at a PEG of 2.04x, which is reasonable for a company with a dominant market position.
- Analyst consensus remains bullish: With a mean recommendation of 2.0 (Buy) and an average target price of $110.81, analysts see substantial upside of 43.4% from the current price of $77.27. Even the low target of $80 implies a modest 3.5% upside, suggesting limited downside risk.
Bearish
- Sharp revenue growth deceleration: Q1 2026 revenue grew only 1.9% YoY, down from 7.4% in Q1 2025, and well below the double-digit growth seen in 2021-2022. This deceleration is driven by softening demand in the US companion animal market and increased competition from generics.
- Massive stock decline and negative momentum: The stock has fallen 47.3% over the past year and is down 51.9% from its 52-week high of $160.48. The 6-month price change is -39.4%, and the stock trades near its 52-week low of $71.47, indicating persistent selling pressure.
- High leverage and debt burden: The debt-to-equity ratio is 2.85x, indicating significant leverage. While the current ratio of 3.03x provides liquidity, the high debt load increases financial risk, especially if earnings decline.
- Wide analyst target range signals uncertainty: The analyst target price ranges from $80 to $160, a spread of $80, reflecting deep disagreement about the company's growth prospects. This uncertainty is a red flag for investors seeking stability.
ZTS Technical Analysis
Zoetis is in a pronounced downtrend, with the stock price falling from a 52-week high of $160.48 to a current level of $77.27, representing a 51.9% decline from its peak. The 1-year price change is -47.3%, and the stock is trading at only 48.1% of its 52-week range, indicating it is near the lows. This positioning suggests that the market is pricing in significant negative sentiment, and the stock is in a bearish phase, with sellers in control and little sign of a reversal.
Beta
0.73
0.73x market volatility
Max Drawdown
-54.8%
Largest decline past year
52-Week Range
$71-$160
Price range past year
Annual Return
-51.0%
Cumulative gain past year
| Period | ZTS Return | S&P 500 |
|---|---|---|
| 1m | -3.2% | +2.4% |
| 3m | -12.3% | +4.6% |
| 6m | -43.0% | +11.7% |
| 1y | -51.0% | +21.4% |
| ytd | -42.3% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ZTS Fundamental Analysis
Zoetis reported Q1 2026 revenue of $2.262 billion, up 1.9% year-over-year, marking a deceleration from the 7.4% growth seen in Q1 2025. The company's revenue growth has slowed from double-digit rates in 2021-2022 to low single digits, with the latest quarter showing the weakest growth in recent periods. Segment data reveals that companion animal products (Dogs and Cats) generated $1.443 billion, representing 63.8% of total revenue, while production animal segments (Cattle, Swine, Poultry) contributed $633 million, with cattle declining. The deceleration is driven by softening demand in key segments, particularly in the US companion animal market, and increased competition from generic products.
Quarterly Revenue
$2.3B
2026-03
Revenue YoY Growth
+1.9%
YoY Comparison
Gross Margin
71.7%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ZTS Overvalued?
Given that Zoetis has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 20.87x, while the forward PE is 10.46x, implying that the market expects a significant increase in earnings per share—the forward EPS estimate is $9.34, compared to trailing EPS of $3.70. This gap suggests that the market is pricing in a dramatic earnings recovery, which may be overly optimistic given the current growth trajectory. The stock's PS ratio is 5.89x, and the PEG ratio is 2.04x, indicating that the stock is not cheap on a growth-adjusted basis.
PE
20.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated. Zoetis carries a debt-to-equity ratio of 2.85x, indicating substantial leverage that could strain cash flows if earnings deteriorate. The company's revenue growth has slowed to just 1.9% YoY in Q1 2026, down from 7.4% a year earlier, and the latest quarter showed the weakest growth in recent periods. This deceleration is driven by softening demand in the US companion animal market and increased competition from generic products, which could pressure margins and profitability. The company's net margin of 28.2% is high, but any further erosion in pricing power could compress it, especially if the company needs to invest more in R&D or marketing to defend its market share.
FAQ
The key risks of holding ZTS include: 1) Financial risk: high debt-to-equity ratio of 2.85x, which could strain cash flows if earnings decline. 2) Competitive risk: increased competition from generic drug manufacturers could erode market share and pricing power. 3) Macro risk: economic downturns could reduce pet spending and livestock demand, impacting revenue. 4) Company-specific risk: the sharp deceleration in revenue growth, particularly in the companion animal segment, could persist and lead to further earnings downgrades. The most severe risk is a continued decline in revenue growth, which would invalidate the forward PE and could push the stock below its 52-week low of $71.47.
The ZTS stock forecast over the next 12 months is uncertain, with a wide range of possible outcomes. In the bull case (25% probability), the stock could reach $110-$160 if growth re-accelerates. In the base case (50% probability), the stock is likely to trade in the $80-$110 range, aligning with the analyst average target of $110.81. In the bear case (25% probability), the stock could fall to $71-$80 if growth stagnates. The most likely scenario is the base case, which assumes low single-digit revenue growth and gradual improvement. The key assumption is that the company can stabilize its revenue growth and maintain its margins, which would support the current valuation.
ZTS stock appears undervalued on a forward basis, with a forward PE of 10.46x, which is low for a company with a dominant market position and strong margins. However, the trailing PE of 20.87x is higher, and the PEG ratio of 2.04x suggests the stock is not cheap on a growth-adjusted basis. The market is pricing in a significant earnings recovery, with forward EPS estimated at $9.34, which may be optimistic given the current growth trajectory. Compared to its own history, the stock is trading near its 52-week low, and the PS ratio of 5.89x is below its historical average. Overall, the stock is fairly valued to slightly undervalued, but the valuation depends heavily on the company's ability to deliver on earnings expectations.
ZTS is a good stock to buy for long-term investors who believe in the company's ability to overcome its current growth challenges. The stock is trading at a forward PE of 10.46x, which is attractive if the company can achieve the estimated EPS of $9.34. Analysts have a Buy rating with an average target of $110.81, implying 43.4% upside. However, the stock has fallen 47.3% over the past year, and the growth deceleration is a major concern. For risk-averse investors, it may be better to wait for signs of stabilization, such as revenue growth re-accelerating above 5% or the stock holding above $80. For those with a high risk tolerance, the current price offers a potential value opportunity.
ZTS is more suitable for long-term investment, given its dominant market position, strong cash flow, and potential for growth recovery. The stock has a beta of 0.73, indicating lower volatility than the market, and pays a dividend yield of 1.59%, providing some income. However, the stock is in a downtrend, and short-term trading could be risky due to the high uncertainty and negative momentum. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the company to execute on its growth strategies and for the market to recognize the value. Short-term traders may find opportunities in the volatility, but the risk of further declines is significant.
